Weinstein MC - Search Results

1

A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7].

Garrison LP Jr, Neumann PJ, Willke RJ, Basu A, Danzon PM, Doshi JA, Drummond MF, Lakdawalla DN, Pauly MV, Phelps CE, Ramsey SD, Towse A, Weinstein MC. Garrison LP Jr, et al. Among authors: weinstein mc. Value Health. 2018 Feb;21(2):161-165. doi: 10.1016/j.jval.2017.12.009. Value Health. 2018. PMID: 29477394 Free article.

2

Impact of referral patterns on the use of chemotherapy for lung cancer.

Earle CC, Neumann PJ, Gelber RD, Weinstein MC, Weeks JC. Earle CC, et al. Among authors: weinstein mc. J Clin Oncol. 2002 Apr 1;20(7):1786-92. doi: 10.1200/JCO.2002.07.142. J Clin Oncol. 2002. PMID: 11919235

3

Long-term persistence in use of statin therapy in elderly patients.

Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Benner JS, et al. Among authors: weinstein mc. JAMA. 2002 Jul 24-31;288(4):455-61. doi: 10.1001/jama.288.4.455. JAMA. 2002. PMID: 12132975

4

Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies.

Weinstein MC, O'Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, Luce BR; ISPOR Task Force on Good Research Practices--Modeling Studies. Weinstein MC, et al. Value Health. 2003 Jan-Feb;6(1):9-17. doi: 10.1046/j.1524-4733.2003.00234.x. Value Health. 2003. PMID: 12535234 Free article.

5

When does quality-adjusting life-years matter in cost-effectiveness analysis?

Chapman RH, Berger M, Weinstein MC, Weeks JC, Goldie S, Neumann PJ. Chapman RH, et al. Among authors: weinstein mc. Health Econ. 2004 May;13(5):429-36. doi: 10.1002/hec.853. Health Econ. 2004. PMID: 15127423 Review.

6

Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis.

Prosser LA, Kuntz KM, Bar-Or A, Weinstein MC. Prosser LA, et al. Among authors: weinstein mc. Value Health. 2004 Sep-Oct;7(5):554-68. doi: 10.1111/j.1524-4733.2004.75007.x. Value Health. 2004. PMID: 15367251 Free article.

7

Can we better prioritize resources for cost-utility research?

Neumann PJ, Rosen AB, Greenberg D, Olchanski NV, Pande R, Chapman RH, Stone PW, Ondategui-Parra S, Nadai J, Siegel JE, Weinstein MC. Neumann PJ, et al. Among authors: weinstein mc. Med Decis Making. 2005 Jul-Aug;25(4):429-36. doi: 10.1177/0272989X05276853. Med Decis Making. 2005. PMID: 16061895

8

Medicare and cost-effectiveness analysis.

Neumann PJ, Rosen AB, Weinstein MC. Neumann PJ, et al. Among authors: weinstein mc. N Engl J Med. 2005 Oct 6;353(14):1516-22. doi: 10.1056/NEJMsb050564. N Engl J Med. 2005. PMID: 16207857 No abstract available.

9

Identifying key parameters in cost-effectiveness analysis using value of information: a comparison of methods.

Groot Koerkamp B, Myriam Hunink MG, Stijnen T, Weinstein MC. Groot Koerkamp B, et al. Among authors: weinstein mc. Health Econ. 2006 Apr;15(4):383-92. doi: 10.1002/hec.1064. Health Econ. 2006. PMID: 16389669

10

Do drug formulary policies reflect evidence of value?

Neumann PJ, Lin PJ, Greenberg D, Berger M, Teutsch S, Mansley E, Weinstein MC, Rosen AB. Neumann PJ, et al. Among authors: weinstein mc. Am J Manag Care. 2006 Jan;12(1):30-6. Am J Manag Care. 2006. PMID: 16402886 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

374 results

Search Page

Filters